A Multi-Center Study Evaluating the Safety of AC-170 0.24%
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of AC-170 0.24% used twice daily in
Healthy Adult Subjects and in Pediatric subjects with a history or family history of atopic
disease (including allergic conjunctivitis).